Esperion Therapeutics Stock News

Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

ANN ARBOR, Mich., April 30, 2020 -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on.

Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR): 4/21/2020 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “se

Equities research analysts predict that Esperion Therapeutics Inc (NASDAQ:ESPR) will post $960,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have provid

BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a report released on Tuesday morning, BidAskClub reports. Several other research firms have als

COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing

Bank of America Corp DE lifted its stake in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 3.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund o

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research note issued to investors on Monday, TipRanks reports. They c

Shareholders in Esperion Therapeutics, Inc. (NASDAQ:ESPR) may be thrilled to learn that the analysts have just...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shareholders will have a reason to smile today, with the analysts making...

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by research analysts at Stifel Nicolaus in a research report issued to clients and investors on Monday, TipRanks reports

"I have been following Dr. Inan Dogan since this outbreak, and he is  a phenomenally intelligent researcher. One month ago, Dr. Dogan's prediction that the total U.S. death toll would be 20,000+ by A

Needham analyst Chad Messer reiterated a Buy rating on Esperion (ESPR) today and set a price target of $158.00. The company's shares closed last Monday at